Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2020 wishlist 🌟
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19 Actions for access 💊💉🔬
      • Explainer: A bold proposal at the WTO by India and South Africa
      • Spotlight on: COVID-19 vaccines
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • COVID-19 Actions for access 💊💉🔬
      • 20 years of Advocacy in Action
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    AC20 Poster - Medicines Still Shouldn't Be A Luxury
    Take Action

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • ⚠️ COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2020 wishlist 🌟
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19 Actions for access 💊💉🔬
      • Explainer: A bold proposal at the WTO by India and South Africa
      • Spotlight on: COVID-19 vaccines
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • COVID-19 Actions for access 💊💉🔬
      • 20 years of Advocacy in Action
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    AC20 Poster - Medicines Still Shouldn't Be A Luxury
    Take Action

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • ⚠️ COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury

Take action!
Get involved
Generic medicines production line

Covid-19: An overview

No patents or profiteering on drugs, tests, and vaccines in pandemic

Get involved!
MSF Access Campaign

“We are seriously concerned with Gilead’s current approach to remdesivir, which may obscure access to this potentially critical treatment for #COVID19”Read our letter to @GileadSciences 👇 bit.ly/2QVeK4E

21:30 - 30 Mar 2020

Navigate

  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search

Get updates

  • Sign up for our newsletter
  • Privacy & data protection information

Contact

MSF Access Campaign
Médecins Sans Frontières
Rue de Lausanne 78
P.O Box 1016
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us on Twitter and Facebook

  • Facebook
  • Twitter
  • Vimeo
Medicines Shouldn't Be A Luxury